MDT - Comprehensive Filing Intelligence

Q3 2026•10-Q•Filed Feb 24, 2026
5.0/10
Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

A jury awarded $382 million in an antitrust case, automatically trebled to $1.146 billion, though the company believes the verdict is inconsistent and plans to appeal.. Cardiovascular Portfolio revenue increased by 13.83%

Top Concerns

  • !The filing lacks specific details on margin drivers or concerns, making it difficult to assess profitability trends comprehensively.
  • !A jury awarded $382 million in an antitrust case, automatically trebled to $1.146 billion, though the company believes the verdict is inconsistent and plans to appeal.
  • !The company has $1.3 billion in outstanding standby letters of credit, bank guarantees, and surety bonds supporting performance and tax obligations.
  • !Regulatory Compliance Costs (EU) (medium)
  • !Competitive Pressures (medium)

Top Positives

  • +Net sales experienced a 9% increase in the three months ended January 23, 2026, and an 8% increase for the nine months ended January 23, 2026, driven by broad business growth and favorable currency impacts.
  • +Operating cash flow and free cash flow showed positive year-over-year increases for the nine-month period, indicating strong cash generation capabilities.
  • +The company provided detailed segment-level revenue growth figures, with Cardiac Rhythm & Heart Failure and Diabetes showing notable increases.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

4.0/10

Management tone is confidently optimistic.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

7.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is moderate with $1.5 billion in identified exposure.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

7.0/10

Overall risk profile shows regulatory compliance costs (eu) as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

7.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.

Related Research

Analysis

EW 10-K Analysis: $534M Charge Year Masks a 60% Margin Machine

Analysis

MDT Q3 FY2026 Earnings: MiniMed Separation Costs Mask Strongest Growth in 10 Quarters

Analysis

Medical Device ROIC Rankings: Why Abbott's 26% Beats Medtronic's 7% (The Gross Margin Paradox)